DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: A pilot study

Gut and Liver

Volumn 7, Issue 1, 2013, Pages 89-95

  Song, Do Seon ^a   Choi, Jong Young ^a   Yoo, Sun Hong ^a   Kim, Hee Yeon ^a   Song, Myeong Jun ^a   Bae, Si Hyun ^a   Yoon, Seung Kew ^a   Chun, Ho Jong ^a   Choi, Byung Gil ^a   Lee, Hae Giu ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Bead; Chemoembolization; Hepatocellular carcinoma; Refractory

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DC BEAD TRANSARTERIAL CHEMOEMBOLIZATION; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MALE; NAUSEA; PAIN; PILOT STUDY; SIDE EFFECT; THERAPY EFFECT; TREATMENT RESPONSE; VOMITING;

EID: 84875104390     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.1.89     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
3. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48 Suppl 1:S20-S37.
4. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
6. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S179-S188.
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
8. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25.
9. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
10. Meza-Junco J, Montano-Loza AJ, Liu DM, et al. Locoregional radiological treatment for hepatocellular carcinoma: which, when and how? Cancer Treat Rev 2012;38:54-62.
11. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563-2567.
12. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:327-332.
13. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
14. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
15. Kudo M, Kubo S, Takayasu K, et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). Hepatol Res 2010;40:686-692.
16. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Bethesda: National Cancer Institute, 2009.
17. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
18. Poyanli A, Rozane? I, Acuna? B, Sencer S. Palliative treatment of hepatocellular carcinoma by chemoembolization. Acta Radiol 2001;42:602-607.
19. Lee JK, Chung YH, Song BC, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol 2002;17:52-58.
20. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991;13:120-127.
21. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006;17:1335-1343.
22. Namur J, Citron SJ, Sellers MT, et al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol 2011;55:1332-1338.
23. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009;44 Suppl 19:112-118.
24. Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. Intervirology 2004;47:191-198.
25. Murakami T, Hori M, Kim T, Kawata S, Abe H, Nakamura H. Multidetector row CT and MR imaging in diagnosing hepatocellular carcinoma. Intervirology 2004;47:209-226.
26. Kudo M. Atypical large well-differentiated hepatocellular carcinoma with benign nature: a new clinical entity. Intervirology 2004;47:227-237.
27. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97:1042-1050.
28. Herber SC, Otto G, Schneider J, et al. Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol 2008;190:1035-1042.
29. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94:1747-1752.
30. Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1545-1552.
31. Malagari K, Alexopoulou E, Chatzimichail K, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008;33:512-519.